Related Experiment Video
Updated: Jul 2, 2026

Humanized Mediator Release Assay as a Read-Out for Allergen Potency
Published on: June 29, 2021
RNA interference: new therapeutics in allergic diseases
Chen-Chen Lee1, Bor-Luen Chiang
1Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan.
Abstract:
Since the RNAi mechanisms were established in 1990, the rapid progression of RNAi application from animal to clinical trails in human diseases has shown its enormous therapeutic potential. In this review, RNAi therapeutics in allergic diseases is discussed, from RNAi mechanisms and design to challenges and potential targets in allergic diseases. Current reported studies on investigating RNAi therapy in vitro and in vivo are also reviewed. Although there are promising studies in RNAi-based therapy, understanding further the detailed mechanisms of RNAi-based therapy and investigating more effective delivery methods are required for future development.
Related Concept Videos
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
Drugs Used in Lower Respiratory Disorders: Overview
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Allergic Drug Reactions
Antiasthma Drugs: Leukotriene Modifiers
Leukotriene modifiers work through two distinct mechanisms:
Allergic Reactions
Allergic Reactions: Anaphylaxis
